Key result
Fetal CHD is linked to faster T2 decay times, indicating lower cerebral tissue oxygenation.
Why the study?
Impairments in fetal oxygen delivery are implicated in brain dysmaturation in CHD, suggesting a role for in utero transplacental oxygen therapy, but fetal cerebral oxygenation and its response to maternal hyperoxia remained to be quantified.
Does brief maternal hyperoxia improve fetal cerebral oxygenation in fetuses with congenital heart disease?
Observational (n=44)
Does brief maternal hyperoxia improve fetal cerebral oxygenation in fetuses with congenital heart disease?
Fetal cerebral tissue oxygenation is lower in complex CHD, but shows variable improvement in response to maternal hyperoxia depending on the specific cardiovascular physiology.
Answers are grounded in this paper and cite their sources.
Lower cerebral oxygenation in CHD fetuses warrants attention; leaves open consistent maternal hyperoxia benefit by lesion physiology.
Background Impairments in fetal oxygen delivery have been implicated in brain dysmaturation seen in congenital heart disease (CHD), suggesting a role for in utero transplacental oxygen therapy. We applied a novel imaging tool to quantify fetal cerebral oxygenation by measuring T2* decay. We compared T2* in fetuses with CHD with controls with a focus on cardiovascular physiologies (transposition or left‐sided obstruction) and described the effect of brief administration of maternal hyperoxia on T2* decay. Methods and Results This is a prospective study performed on pregnant mothers with a prenatal diagnosis of CHD compared with controls in the third trimester. Participants underwent a fetal brain magnetic resonance imaging scan including a T2* sequence before and after maternal hyperoxia. Comparisons were made between control and CHD fetuses including subgroup analyses by cardiac physiology. Forty‐four mothers (CHD=24, control=20) participated. Fetuses with CHD had lower total brain volume (238.2 mm 3 , 95% CI, 224.6–251.9) compared with controls (262.4 mm 3 , 95% CI, 245.0–279.8, P =0.04). T2* decay time was faster in CHD compared with controls (beta=−14.4, 95% CI, −23.3 to −5.6, P =0.002). The magnitude of change in T2* with maternal hyperoxia was higher in fetuses with transposition compared with controls (increase of 8.4 ms, 95% CI, 0.5–14.3, P =0.01), though between‐subject variability was noted. Conclusions Cerebral tissue oxygenation is lower in fetuses with complex CHD. There was variability in the response to maternal hyperoxia by CHD subgroup that can be tested in future larger studies. Cardiovascular physiology is critical when designing neuroprotective clinical trials in the fetus with CHD.
No takes yet. Share an insight, caveat, or question.
Peyvandi et al. (2020) conducted an observational in Congenital Heart Disease (CHD) in fetuses (n=44). Maternal hyperoxia vs. Controls (fetuses without CHD) was evaluated on T2 decay time (fetal cerebral oxygenation) (beta -14.4, 95% CI -23.3 to -5.6, p=0.002). Fetuses with congenital heart disease had faster T2 decay times compared with controls, indicating lower cerebral tissue oxygenation.
Synapse has enriched 10 related papers. Consider them for comparative context: